Literature DB >> 29715531

Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer.

Peixiao Tang1, Qiaomei Sun1, Hongqin Yang1, Bin Tang1, Hongyu Pu1, Hui Li2.   

Abstract

This study aims to design a novel nano-sized anticancer drug delivery system that can enhance the therapeutic effects of the loaded drug. With this idea in mind, this work reported the design and characterization of epigallocatechin-3-gallate (EGCG) functionalized chitin (CH) derivative, and its application in nano-drug delivery system. The EGCG-functionalized CH (CE) polymer was firstly prepared and characterized. The nanoparticles (NPs) of CE-loaded honokiol (HK), which was prepared by ionic crosslinking, exhibited a size of 80 nm, zeta potential of +33.8 mV, and spherical morphology. The antitumor activity of the CE-HK NPs in vitro and in vivo was investigated and compared to free HK. As a result, the CE-HK NPs can effectively inhibited cell proliferation of HepG2 cell by inhibiting more cells in the G2/M phase and decreasing mitochondrial membrane potential. The CE-HK NPs (40 mg/kg) inhibited tumor growth by 83.55% (p < 0.05), which was far higher than the 30.15% inhibition of free HK (40 mg/kg). The proposed delivery system exhibits better tumor selectivity and growth reduction both in vitro and in vivo, and does not induce any side effects. Therefore, the CE-HK NPs may act as an effective delivery system of liver cancer agent HK.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chitin (PubChem CID: 6857375); EGCG; Epigallocatechin-3-gallate (PubChem CID: 65064); Honokiol; Honokiol (PubChem CID: 72303); Liver cancer; Nanoparticles; Synergistic effects

Mesh:

Substances:

Year:  2018        PMID: 29715531     DOI: 10.1016/j.ijpharm.2018.04.060

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

Review 1.  Nanodelivery of phytobioactive compounds for treating aging-associated disorders.

Authors:  Oleh Lushchak; Olha Strilbytska; Alexander Koliada; Alina Zayachkivska; Nadia Burdyliuk; Ihor Yurkevych; Kenneth B Storey; Alexander Vaiserman
Journal:  Geroscience       Date:  2019-11-04       Impact factor: 7.713

2.  Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ∆pKa Rule.

Authors:  Xiaoshuang He; Yuanfeng Wei; Shiru Wang; Jianjun Zhang; Yuan Gao; Shuai Qian; Zunting Pang; Weili Heng
Journal:  Pharm Res       Date:  2022-07-14       Impact factor: 4.580

Review 3.  Honokiol: A Review of Its Anticancer Potential and Mechanisms.

Authors:  Chon Phin Ong; Wai Leong Lee; Yin Quan Tang; Wei Hsum Yap
Journal:  Cancers (Basel)       Date:  2019-12-22       Impact factor: 6.639

Review 4.  Flavonoid Nanoparticles: A Promising Approach for Cancer Therapy.

Authors:  Malgorzata Dobrzynska; Marta Napierala; Ewa Florek
Journal:  Biomolecules       Date:  2020-09-02

Review 5.  Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization.

Authors:  Gennaro Sanità; Barbara Carrese; Annalisa Lamberti
Journal:  Front Mol Biosci       Date:  2020-11-26

6.  Design, Formulation and in vivo Evaluation of Novel Honokiol-Loaded PEGylated PLGA Nanocapsules for Treatment of Breast Cancer.

Authors:  Yusuf A Haggag; Rowida R Ibrahim; Amin A Hafiz
Journal:  Int J Nanomedicine       Date:  2020-03-09

Review 7.  Emerging Nanopharmaceuticals and Nanonutraceuticals in Cancer Management.

Authors:  Lavinia Salama; Elizabeth R Pastor; Tyler Stone; Shaker A Mousa
Journal:  Biomedicines       Date:  2020-09-12

Review 8.  Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.

Authors:  Anita Bakrania; Gang Zheng; Mamatha Bhat
Journal:  Pharmaceutics       Date:  2021-12-25       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.